Formononetin Antagonizes Osteosarcoma Metastasis by Targeting CD44: An Integrated Multi-Omics Study
- 31 July 2026
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 160, 158612
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Youth Science Foundation of Guangxi Medical University
- China Postdoctoral Science Foundation
- Natural Science Foundation of Guangxi Province
This publication has 67 references indexed in Scilit:
- In silico off-target profiling for enhanced drug safety assessmentActa Pharmaceutica Sinica B, 2024
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor MerlinInternational Journal of Cancer, 2020
- EGFL7 regulates sprouting angiogenesis and endothelial integrity in a human blood vessel modelBiomaterials, 2019
- In vitro and in vivo studies of antiosteosarcoma activities of formononetinJournal of Cellular Physiology, 2019
- Exosomes Derived from Human Primary and Metastatic Colorectal Cancer Cells Contribute to Functional Heterogeneity of Activated Fibroblasts by Reprogramming Their ProteomeProteomics, 2018
- Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck CancerCell, 2017
- CD44: More than a mere stem cell markerThe International Journal of Biochemistry & Cell Biology, 2016
- The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information RepositoryJournal of Digital Imaging, 2013
- Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcomaJournal of Surgical Oncology, 2013